Optimal Rituximab Monotherapy in Splenic Marginal Zone Lymphoma (SMZL): A Case Report and Brief Review

CONCLUSION: Our analysis found no statistically significant difference between rituximab monotherapy and rituximab combined with chemotherapy, while rituximab treatments resulted in better therapeutic effects than chemotherapy. Rituximab monotherapy has favorable therapeutic effects and minor adverse effects (AEs) in treating SMZL.PMID:37937574 | DOI:10.2174/0115748928247369231024112003
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Authors: Source Type: research